Resveratrol Exerts Differential Effects in Vitro and in Vivo against Ovarian Cancer Cells |
Stakleff, Kimberly Sloan
(Kenneth Calhoun Research Laboratory, Akron General Medical Center)
Sloan, Tricia (Kenneth Calhoun Research Laboratory, Akron General Medical Center) Blanco, Denise (Kenneth Calhoun Research Laboratory, Akron General Medical Center) Marcanthony, Sharon (Department of Obstetrics and Gynecology, Akron General Medical Center) Booth, Tristan D. (Clinical and Innovative Development, Pharmascience, Inc.) Bishayee, Anupam (Department of Pharmaceutical and Administrative Sciences, School of Pharmacy, American University of Health Sciences) |
1 | Aalto ML, Collan Y (1986). Periodic acid-Schiff stain as a prognostic indicator in serous and mucinous ovarian tumors. Int J Gynaecol Obstet, 24, 27-34. DOI |
2 | Aggarwal BB, Bhardwaj A, Aggarwal RS, et al (2004). Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res, 24, 2783-40. |
3 | Athar M, Back JH, Kopelovich L, Bickers DR, Kim Al (2009). Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys, 486, 95-102. DOI |
4 |
Banerjee S, Bueso Ramos C, Aggarwal BB (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor- |
5 | Becher OJ, Holland EC (2006). Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res, 66, 3355-9. DOI |
6 | Bishayee A (2009). Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res, 2, 409-18. DOI ScienceOn |
7 | Bishayee A, Dhir N (2009). Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem-Biol Interact, 179, 131-44. DOI ScienceOn |
8 | Bishayee A (2012). Current advances in cancer prevention and treatment by natural products. Curr Pharm Biotechnol, 13, 115-6. DOI |
9 | Bjorklund M, Roos J, Gogvadze V, Shoshan M (2011). Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low dose-dose platinum treatment. Cancer Chemother Pharmacol, 68, 1459-67. DOI |
10 | Bove K, Lincoln DW, Tsan MF (2001). Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun, 291, 1001-5. |
11 | Brard L, Granai CO, Swamy N (2006). Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecol Oncol, 100, 116-27. DOI ScienceOn |
12 | Brewer MA, Johnson K, Follen M, Gershenson D, Bast R, Jr (2003). Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res, 9, 20-30. |
13 |
Cao Z, Fang J, Xia C, Shi X, Jiang BH (2004). trans-3,4,5'- Trihydroxystibene inhibits hypoxia-inducible factor 1 |
14 | Crowell JA, Korytko PJ, Morrissey Rl, Booth TD, Levine BS (2004). Resveratrol-associated renal toxicity. Toxicol Sci, 82, 614-9. DOI |
15 | Delmas D, Solary E, Latruffe N (2011). Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med Chem, 18, 1100-21. DOI |
16 | Dennis T, Fanous M, Mousa S (2009). Natural products for chemopreventive and adjunctive therapy in oncologic disease. Nutr Cancer, 61, 587-97. DOI |
17 | Feki A, Jefford CE, Berardi P, et al (2005). BARD1 induces apoptosis by catalyzing phosphorylation of p53 by DNAdamage response kinase. Oncogene, 24, 3726-37. DOI |
18 | Fremont L (2000). Biological effects of resveratrol. Life Sci, 66, 663-73. DOI ScienceOn |
19 | Gescher AJ, Steward WP (2003). Relationship between mechanisms, bioavailability, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev, 12, 953-7. |
20 | Gullett NP, Ruhul Amin AR, Bayraktar S, et al. (2010) Cancer prevention with natural compounds. Semin Oncol, 37, 258-81. DOI |
21 | Guo L, Peng Y, Yao J, (2010). Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice. Cancer Biother Radiopharm, 25, 471-7. DOI |
22 | Harikumar KB, kunnumakkara AB, Sethi G, et al. (2010) Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer, 127, 257-68. |
23 | Harper CE, patel BB, Wang J, et al (2007). Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis, 28, 1946-53. DOI ScienceOn |
24 | Hebbar V, Shen G, Hu R, et al. (2005) Toxicogenomics of resveratrol in rat liver. Life Sci, 76, 2299-314. DOI ScienceOn |
25 | Hoekstra A, Rodriguez GC (2009). Chemoprevention of ovarian cancer. Cancer Treat Res, 149, 3-34. DOI |
26 | Hsu SM, Raine L, Fanger H (1981). Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between (ABC) and unlabeled antibody (PAP) procedures. J Histochem Cytochem, 29, 577-80. DOI |
27 | Jang M, Cai L, Udeani GO, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218-20. DOI ScienceOn |
28 | Kueck A, Opipari AW, Griffith KA, et al. (2007) Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol, 107, 450-7. DOI |
29 | Kundu JK, Surh YJ (2008). Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett, 269, 243-61. DOI |
30 | Lee MH, Choi BY, Kundu JK, et al (2009). Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res, 69, 7449-58. DOI |
31 | Li ZG, Hong T, Shimada Y, et al (2002). Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis, 23, 1531-6. DOI ScienceOn |
32 | Lin C, Crawford DR, Lin S, et al. (2011) Inducible COX- 2 dependent apoptosis in human ovarian cancer cells. Carcinogenesis, 32, 19-26. DOI |
33 | Marimuthu P, Kaur K, Kandalam U, et al. (2011). Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation. J Med Food, 14, 46-52. DOI |
34 | Medvetz DA, Stakleff KD, Schreiber T, et al. (2007) Ovarian cancer activity of cyclic amine and thiaether metal complexes. J Med Chem, 50, 1703-6. DOI |
35 | Mills GB (2002). Mechanisms underlying chemoprevention of ovarian cancer. Clin Cancer Res, 8, 7-10. |
36 | NIH Consensus Development Panel on Ovarian Cancer (1995). Ovarian cancer: screening, treatment and follow-up. J Am Med Assoc, 273, 491-7. DOI |
37 | Niles RM, Cook CP, Meadows GG, et al. (2006). Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr, 136, 2542-6. |
38 | Niles RM, Mcfarland M, Weimer MB, et al. (2003) Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett, 190, 157-63. DOI ScienceOn |
39 | Opipari JR, AW, Tan L, et al (2004). Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res, 64, 696-703. DOI ScienceOn |
40 |
Park SY, Jeong KJ, Lee J, et al. (2007) Hypoxia enhances, LPAinduced HIF- |
41 | Raj MHG, Abd Elmageed ZY, Zhou J, et al (2008). Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells. Gynecol Oncol, 110, 432-8. DOI |
42 | Rezk YA, Balulad SS, Keller RS, Bennett JA (2006). Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic can cell lines and in rodent heart. Am J Obstet Gynecol, 194, 23-6. DOI |
43 | Rose GS, Toco LM, Granger GA, et al (1996) Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol, 175, 593-9. DOI |
44 | Sankaranarayanan R, Ferlay J (2006). Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol, 20, 207-25. DOI |
45 | Schneider Y, Duranton B, Gosse F, et al (2001) Resveratrol inhibits intestinal tumorigenesis and modulates host-defenserelated gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer, 39, 102-7. DOI |
46 | Schumacher JJ, Dings RPM, Costin J, et al (2007). Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res, 67, 3683-90. DOI |
47 | Sengottuvelan M, Viswanathan P, Nalini N (2006). Chemopreventive effect of trans-resveratrol - a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis, 27, 1038-46. DOI ScienceOn |
48 | Shukla Y, Singh R (2011). Resveratrol and cellular mechanisms of cancer prevention. Ann NY Acad Sci, 1215, 1-8. DOI |
49 | Siegel R, Naishadham, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. DOI ScienceOn |
50 | Sloan Stakleff KD, Rouse AG, Ryan AP, Haller NA, Von Gruenigen VE (2005). A novel early-stage orthotopic model for ovarian cancer in the Fischer 344 rat. Int J Gynecol Cancer, 15, 246-54. DOI |
51 | Sloan Stakleff KD, Von Gruenigen VE (2003). Rodent models for ovarian cancer research. Int J Gynecol Cancer, 13, 405-12. DOI |
52 | Smith ER, Daly MB, Xu XX (2004). A mechanism for cox-2 inhibitor anti-inflammatory activity in chemoprevention of epithelial cancers. Cancer Epidem Biomarkers Prev, 13, 144-5. DOI |
53 | Stan SD, Kar S, Stoner GD, Singh SV (2008). Bioactive food components and cancer risk reduction. J Cell Biochem, 104, 339-56. DOI ScienceOn |
54 | Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ (1997). Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med, 216, 201-10. DOI |
55 | Subramanian L, Youssef S, Bhattacharya S, et al. (2010) Resveratrol: challenges in translation to the clinic - a critical discussion. Clin Cancer Res, 16, 5942-8. DOI |
56 | Teicher BA (2006). Tumor models for efficacy determination. Mol Cancer Ther, 5, 2435-43. DOI |
57 | Tessitore L, Davit A, Sarotto I, Caderni G (2000). Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21 (CIP) expression. Carcinogenesis, 21, 1619-22. DOI ScienceOn |
58 | Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sciafani RA (2005). Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis, 26, 1978-87. DOI |
59 | Visintin I, Feng A, Longton G, et al (2008). Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res, 14, 1065-72. DOI ScienceOn |
60 | Weng CJ, Yen GC (2012). Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev, 38, 76-87. DOI |
61 | Yang SH, Kim JS, Oh TJ, et al (2003) Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Int J Oncol, 22, 741-50. |
62 | Zhou H-B, Chen J-J, Wang W-X, Cai J-T, Du Q (2005). Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol, 11, 280-4. DOI |
![]() |